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Abstract
Thrombocytopenia is a common finding in critically ill patients.
Heparin-induced thrombocytopenia is an infrequent cause of a low
platelet count. Intensivists should use the diagnostic classification
system developed by the International Society on Thrombosis and
Haemostasis to diagnose heparin-induced thrombocytopenia. The
clinical relevance of the presence of anti-heparin/platelet factor 4
complex autoantibodies in the absence of clinical heparin-induced
thrombocytopenia remains unknown.
Intensivists frequently encounter thrombocytopenia in the
critically ill, which has an incidence of 30% to 50% in such
patients. The low platelet count indicates the severity of
disease in these patients and has prognostic significance.
Most often, the thrombocytopenia is a transient phenomenon,
and recovery of the platelet count often reflects clinical
improvement. On the other hand, a persistent low platelet
count or relapse of thrombocytopenia often portends clinical
deterioration and death.
There are many potential aetiologies of thrombocytopenia in
the critically ill, including loss, dilution, consumption,
destruction and impaired production of platelets. Among the
various types of thrombocytopenia, heparin-induced thrombo-
cytopenia (HIT), in which anti-heparin/platelet factor 4 complex
antibodies (the so-called HIT antibodies) play a central role, is
regarded as the most common drug-induced immune-
mediated thrombocytopenia. HIT, which involves a para-
doxical association of a procoagulant state with an anti-
coagulant drug, is feared because of the possible occurrence
of life-threatening and potentially fatal venous and arterial
thromboembolic complications. It is implicated by the
association of treatment with unfractionated heparin or low-
molecular-weight heparin and development of thrombo-
cytopenia, both of which are common in the ICU. HIT is
actively diagnosed because of the preventability of its
sequelae.
At the turn of the century the incidence of HIT in the critically
ill was largely unknown. Seven investigations were begun at
around that time, and slowly but surely the incidence of HIT in
the critically ill has emerged. In the preceding issue of Critical
Care, Gettings and coworkers [1] report their retrospective
observations in surgical critically ill patients, in which they
focus on the incidence of HIT antibody positivity, the
incidence of HIT and the clinical relevance of HIT antibodies.
Over 2 years a total of 2,046 patients were admitted, and
there was suspicion of HIT in 210 of these. Nineteen patients
tested positive for HIT antibodies, yielding an incidence of
0.9% of seroconversion and HIT. These patients were at
increased risk for death or major thromboembolic complica-
tions and prolonged length of stay in the ICU in comparison
with matched control individuals.
Two important comments can be made based on these
findings. First, one can contest whether all 19 patients
suffered from HIT, because seroconversion does not prove
that HIT has developed. Stimulated by the peer review
process, the authors used, retrospectively, the diagnostic
classification system developed by the Scientific and
Standardization Committee Subcommittee on Platelet
Immunology of the International Society on Thrombosis and
Haemostasis, which can be regarded as the current
reference method [2]. Fifteen patients had an intermediate
pretest probability and four patients had a high pretest
probability of HIT. The diagnosis of HIT can be made if
intermediate or high pretest probability is supported by the
presence of HIT antibodies and proof of platelet aggregation.
In other words, laboratory confirmation of HIT should consist
of an antibody assay and a functional assay. In about half of
cases in which there is a positive antibody test, the functional
assay will be negative. Gettings and coworkers [1] did not
use a functional test, and so the reported incidence of 0.9%
is the incidence of seroconversion and not necessarily the
incidence of HIT, which probably was lower.
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In the other six studies that investigated the incidence of HIT
antibody positivity and HIT in general populations of critically
ill patients [3-8], similar results were reported. In 261 patients
in a medical-surgical ICU, no cases of HIT antibody positivity
and no HIT were found [3]. In 267 patients treated in a
combined intensive and coronary care unit, an incidence of
0.39% (95% confidence interval 0.01% to 2.1%) of HIT was
reported [4]. In 55 patients treated in a general ICU, an
incidence of 39.5% seroconversion was detected but no
cases of HIT were identified [5]. In 233 patients in a medical
ICU, an HIT incidence of 2.5% was found [6]. In 43 patients
admitted for longer than 36 hours in a medical-surgical ICU, a
seroconversion incidence of 16.3% and an incidence of HIT
of 4.7% were demonstrated [7]. Finally, in 64 patients with
multiple organ dysfunction syndrome in a surgical ICU,
incidences of 4.7% for seroconversion and 4.7% for HIT
were detected [8].
Second, the authors tried to analyze the clinical relevance of
the presence of HIT antibodies, but they could have chosen
their control group more carefully. The control group
comprised a mixture of patients, most of whom were not
suspected of having HIT and were therefore not tested. The
authors could have drawn firmer conclusions if they had
chosen the control group from among patients suspected of
having HIT but who tested negative for HIT antibodies.
Nevertheless, their results are in accord with those of a large
study conducted in cardiac surgery patients in the critical
care setting, of whom 6.6% were positive for HIT antibodies
but who did not have HIT [9]. Patients with HIT antibodies
required prolonged mechanical ventilation, developed acute
renal failure necessitating haemodialysis, had a prolonged
length of stay in the ICU, and consumed significant additional
critical care resources.
The clinical relevance of the presence of HIT antibodies
remains unknown. Other antiplatelet autoantibodies can be
detected in patients with sepsis and in those undergoing
cardiopulmonary bypass procedures [10]. These auto-
antibodies and HIT antibodies without platelet-aggregating
properties may well represent important autoimmune
mechanisms in severe disease, but they may be regarded as
an epiphenomenon of severe disease as well. To date, no
therapy directed against antiplatelet autoantibodies is of
proven value in the critical care setting.
In conclusion, intensivists should be aware that HIT is a rare
disease. Many critically ill patients will develop a low platelet
count, but the likelihood that HIT is the cause is far less than
that for many other causes. Intensivists should employ the
tools provided by the International Society on Thrombosis
and Haemostasis to diagnose HIT and should combine
clinical data with sufficient laboratory data. The presence of
HIT antibodies alone is not enough - a positive test is not
necessarily a disease!
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